Rushing this process offers no benefit and carries real risk of severe side effects that could compromise the entire protocol
If using a syringe, gently push the plunger until all the medication is delivered
[13] [14] [15] [16] [17] Adverse events are most commonly gastrointestinal symptoms such as nausea and diarrhea, with relatively low rates of study discontinuation and infrequent serious adverse events reported during trials
Technically, when the FDA first yanked tirzepatide off its shortage list in October 2024, both 503As and 503Bs could no longer legally make copycats (with one notable exception for the smaller 503As, who could still fill individual prescriptions if there was a medical reason the patient needed a slightly different version than the brand-name drugmore on this later)
The results of the clinical trial released Thursday have not yet been published in a peer-reviewed medical journal, nor have they undergone peer review
Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man
